GlobeStar Therapeutics Corporation (GSTC)
USD 0.0
(-16.67%)
USD 0.0
(-16.67%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.86 Million USD | 0.0% |
| 2022 | -1.26 Million USD | 86.09% |
| 2021 | -9.09 Million USD | -2894.76% |
| 2020 | -303.67 Thousand USD | 3.86% |
| 2019 | -315.87 Thousand USD | 10.02% |
| 2018 | -351.05 Thousand USD | 23.83% |
| 2017 | -460.9 Thousand USD | -196.44% |
| 2016 | -155.48 Thousand USD | 77.72% |
| 2015 | -697.74 Thousand USD | -52.49% |
| 2014 | -457.56 Thousand USD | 29.08% |
| 2013 | -645.19 Thousand USD | 31.72% |
| 2012 | -944.96 Thousand USD | -1646.54% |
| 2011 | -54.1 Thousand USD | -2503.71% |
| 2010 | -2078.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -167.58 Thousand USD | -7.51% |
| 2024 Q3 | -193.35 Thousand USD | -15.38% |
| 2024 Q1 | -155.87 Thousand USD | 45.84% |
| 2023 Q3 | -1.27 Million USD | -800.53% |
| 2023 Q2 | -142.05 Thousand USD | 8.49% |
| 2023 Q1 | -155.24 Thousand USD | 48.23% |
| 2023 FY | -1.26 Million USD | 0.0% |
| 2023 Q4 | -287.78 Thousand USD | 77.5% |
| 2022 Q1 | -166.29 Thousand USD | 95.93% |
| 2022 Q2 | -662.31 Thousand USD | -298.28% |
| 2022 FY | -1.26 Million USD | 86.09% |
| 2022 Q4 | -299.84 Thousand USD | -119.48% |
| 2022 Q3 | -136.61 Thousand USD | 79.37% |
| 2021 Q4 | -4.08 Million USD | 8.77% |
| 2021 Q2 | -470.4 Thousand USD | -679.42% |
| 2021 Q3 | -4.47 Million USD | -851.97% |
| 2021 FY | -9.09 Million USD | -2894.76% |
| 2021 Q1 | -60.35 Thousand USD | 53.39% |
| 2020 FY | -303.67 Thousand USD | 3.86% |
| 2020 Q1 | -74.23 Thousand USD | -20.06% |
| 2020 Q2 | -51.38 Thousand USD | 30.77% |
| 2020 Q4 | -129.48 Thousand USD | -166.64% |
| 2020 Q3 | -48.56 Thousand USD | 5.5% |
| 2019 Q2 | -70.78 Thousand USD | 45.29% |
| 2019 Q3 | -53.85 Thousand USD | 23.91% |
| 2019 Q4 | -61.83 Thousand USD | -14.8% |
| 2019 Q1 | -129.39 Thousand USD | -16.66% |
| 2019 FY | -315.87 Thousand USD | 10.02% |
| 2018 Q3 | -69.72 Thousand USD | -67.1% |
| 2018 Q1 | -128.69 Thousand USD | -414.39% |
| 2018 FY | -351.05 Thousand USD | 23.83% |
| 2018 Q4 | -110.91 Thousand USD | -59.08% |
| 2018 Q2 | -41.72 Thousand USD | 67.58% |
| 2017 FY | -460.9 Thousand USD | -196.44% |
| 2017 Q4 | -25.01 Thousand USD | 68.41% |
| 2017 Q3 | -79.18 Thousand USD | 33.93% |
| 2017 Q2 | -119.86 Thousand USD | 49.39% |
| 2017 Q1 | -236.83 Thousand USD | 0.0% |
| 2016 Q3 | -25.29 Thousand USD | 73.76% |
| 2016 FY | -155.48 Thousand USD | 77.72% |
| 2016 Q2 | -96.39 Thousand USD | 26.72% |
| 2016 Q1 | -131.54 Thousand USD | 45.9% |
| 2015 Q2 | -149.86 Thousand USD | -52.6% |
| 2015 FY | -697.74 Thousand USD | -52.49% |
| 2015 Q1 | -98.2 Thousand USD | -113.1% |
| 2015 Q4 | -243.13 Thousand USD | -17.72% |
| 2015 Q3 | -206.53 Thousand USD | -37.81% |
| 2014 Q4 | -46.08 Thousand USD | 68.6% |
| 2014 Q2 | -114.8 Thousand USD | 37.92% |
| 2014 FY | -457.56 Thousand USD | 29.08% |
| 2014 Q3 | -146.75 Thousand USD | -27.84% |
| 2014 Q1 | -184.92 Thousand USD | 43.78% |
| 2013 Q1 | -59.14 Thousand USD | -15.69% |
| 2013 Q4 | -328.92 Thousand USD | -169.97% |
| 2013 FY | -645.19 Thousand USD | 31.72% |
| 2013 Q3 | -121.83 Thousand USD | 9.95% |
| 2013 Q2 | -135.29 Thousand USD | -128.75% |
| 2012 Q4 | -51.12 Thousand USD | 92.92% |
| 2012 Q3 | -722.21 Thousand USD | -602.1% |
| 2012 Q2 | -102.86 Thousand USD | -49.59% |
| 2012 Q1 | -68.76 Thousand USD | -112.07% |
| 2012 FY | -944.96 Thousand USD | -1646.54% |
| 2011 Q2 | -2100.00 USD | 2.33% |
| 2011 Q1 | -2150.00 USD | 0.0% |
| 2011 Q3 | -17.42 Thousand USD | -729.95% |
| 2011 Q4 | -32.42 Thousand USD | -86.04% |
| 2011 FY | -54.1 Thousand USD | -2503.71% |
| 2010 FY | -2078.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | -1223.121% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -171.398% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -987.036% |
| CytoDyn Inc. | -18.05 Million USD | 89.676% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 96.84% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | -257833.62% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -2.645% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 63.041% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -6124.526% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -927.286% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | 80.791% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 96.641% |
| SQZ Biotechnologies Company | -75.82 Million USD | 97.541% |
| Resverlogix Corp. | -12.74 Million USD | 85.376% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -378.571% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 119.137% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 24.068% |
| Mesoblast Limited | -84.14 Million USD | 97.784% |
| GB Sciences, Inc. | -1.42 Million USD | -31.247% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -171.398% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 89.554% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 45.246% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 71.956% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 41.155% |
| ContraFect Corporation | -56.88 Million USD | 96.723% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 32.225% |
| BioStem Technologies, Inc. | -7.77 Million USD | 76.033% |
| LadRx Corporation | -3.82 Million USD | 51.241% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 88.252% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -66.61% |
| CSL Limited | 3.7 Billion USD | 100.05% |
| Biomind Labs Inc. | -1 Million USD | -84.664% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -100.173% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 102.278% |
| Nascent Biotech, Inc. | -2.22 Million USD | 16.391% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 97.403% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 137.934% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 152.666% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -21.374% |
| Marizyme, Inc. | -34.08 Million USD | 94.53% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 77.672% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -230.139% |
| Zenith Capital Corp. | -8.94 Million USD | 79.153% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 34.595% |
| Halberd Corporation | -75.05 Thousand USD | -2384.171% |
| Genus plc | 6.4 Million USD | 129.131% |
| Pharming Group N.V. | -4.87 Million USD | 61.792% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 6.147% |
| IMV Inc. | -38.67 Million USD | 95.179% |
| Affymax, Inc. | -15.04 Million USD | 87.609% |
| SYBLEU INC | -149.18 Thousand USD | -1149.745% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -78.58% |
| Enzolytics Inc. | -2.14 Million USD | 13.237% |
| argenx SE | -425.04 Million USD | 99.561% |
| AVAX Technologies, Inc. | 6.69 Million USD | 127.856% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -32.98% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -39.608% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 50.236% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -7307.112% |
| Cell Source, Inc. | -4.32 Million USD | 56.897% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -285.948% |
| Q BioMed Inc. | -3.44 Million USD | 45.892% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 56.013% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -48.437% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 29.045% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 59.067% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 96.609% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 35.739% |
| Rebus Holdings, Inc. | -664 Thousand USD | -180.779% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -89.458% |
| Skye Bioscience, Inc. | -13.67 Million USD | 86.363% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 7.003% |
| ONE Bio Corp. | 13.68 Million USD | 113.627% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 3.531% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -65.736% |
| Agentix Corp. | -1.37 Million USD | -35.911% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 36.14% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -18.046% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -10601.854% |
| Kadimastem Ltd | -3.04 Million USD | 38.677% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -612.337% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -348.728% |
| NovAccess Global Inc. | -2.46 Million USD | 24.42% |
| Itoco Inc. | -919.14 Thousand USD | -102.839% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -747.141% |
| Qrons Inc. | -643.67 Thousand USD | -189.644% |
| Mobile Lads Corp. | -554.55 Thousand USD | -236.195% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.552% |
| International Stem Cell Corporation | -663 Thousand USD | -181.202% |
| Bioxytran, Inc. | -3.82 Million USD | 51.196% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -3441.736% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -9066.028% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 94.859% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -15.227% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -153.368% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 40.072% |
| Neutra Corp. | -229.48 Thousand USD | -712.411% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 89.37% |
| PureTech Health plc | -146.19 Million USD | 98.725% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 91.325% |
| IXICO plc | -1.43 Million USD | -29.74% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 80.356% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.469% |
| CSL Limited | 3.81 Billion USD | 100.049% |
| Cellectis S.A. | -108.85 Million USD | 98.287% |